Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting
Kintara Therapeutics (Nasdaq: KTRA) announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 14-19 in Orlando. The company will present two posters focused on its lead program, VAL-083, aimed at treating recurrent glioblastoma. The presentations, on April 17, will cover case reports of RELA fusion-positive ependymoma and VAL-083’s application in glioblastoma patients under expanded access. Kintara, based in San Diego, is dedicated to developing novel cancer therapies to address significant medical needs.
- None.
- None.
SAN DIEGO, March 15, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company will be presenting two posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, April 14-19. The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma.
Data presentations:
Session Title: Late-Breaking Research: Clinical Research 1 / Endocrinology
Poster Section: 34
Presentation Time: Monday, April 17, 2023 - 1:30 to 5:00 p.m. ET
- Title: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports
Abstract Number: LB126 - Title: VAL-083 in patients with recurrent glioblastoma treated under expanded access program
Abstract Number: LB127
Abstracts are currently available on the AACR website. A copy of the presentations will also be available after the closure of the meeting on April 19, under the Publications and Abstracts tab of the News & Media section of the Company's website.
ABOUT KINTARA
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a 'first-in-class', small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.
Kintara also has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of
For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE Study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; global unrest; and the continued impact of the COVID-19 pandemic. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2022, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS
Investors
LifeSci Advisors
Mike Moyer, Managing Director
617.308.4306
mmoyer@lifesciadvisors.com
Media Inquiries
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
858.717.2310
646.942.5604
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-two-posters-at-the-2023-american-association-for-cancer-research-annual-meeting-301772555.html
SOURCE Kintara Therapeutics
FAQ
What is Kintara Therapeutics presenting at the 2023 AACR Annual Meeting?
When is Kintara's presentation at the AACR Annual Meeting?
What are the titles of Kintara's posters at the AACR event?
What does VAL-083 target in cancer treatment?
Where is Kintara Therapeutics located?
